Landscapes / Oncology
PD-(L)1 x VEGF bispecifics landscape
17 drugs in 187 active trials · Phase 2 and later · updated 16 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs17
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-1/VEGF bispecific antibody |
Akeso +1 · Public 9926.HK · SMMT |
Approved in China | 1 Dec 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Advanced Solid Tumors and 95 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Junshi Biosciences · Public 1877.HK |
Phase 3 | 27 Nov 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 27 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Malignant Solid Tumors, Hepatocellular Carcinoma and 8 more | ||||
| Open drug page | |||||
PD-L1/VEGF-A bispecific antibody |
BioNTech +1 · Public BNTX · BMY |
Phase 3 | 1 Jan 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, SCLC and 49 more | ||||
| Open drug page | |||||
PD-L1 antibody fused to a VEGFR1 domain (PD-L1/VEGF) |
Huahai Pharmaceutical (Huaota) · Public 600521.SS |
Phase 3 | 15 Jan 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 15 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced NSCLC, Advanced Endometrial Cancer and 3 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
RemeGen +1 · Public 9995.HK · ABBV |
Phase 3 | 12 May 2027Phase 2/3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 12 May 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Solid Tumor and 6 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Sinocelltech · Public 688520.SS |
Phase 3 | Jul 2027Phase 3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Advanced Malignant Solid Tumours, Non-Small Cell Lung Carcinoma (NSCLC) | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Pfizer +1 · Public PFE · 1530.HK |
Phase 3 | 18 Oct 2027Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 18 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer and 59 more | ||||
| Open drug page | |||||
PD-L1/VEGF bispecific antibody |
Henlius · Public 2696.HK |
Phase 2/3 | 30 Dec 2030Phase 2/3 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 30 Dec 2030 · Phase 2/3 trial completes | ||||
| Also tested for | Advanced/Metastatic Solid Tumors, NSCLC and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Dec 2026Phase 2 trial completes | |||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor Cancer, Advanced Solid Tumor and 1 more | ||||
| Open drug page | |||||
PD-1/VEGF/CTLA-4 trispecific antibody |
CStone · Public 2616.HK |
Phase 1/2 | Dec 2026First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) | ||
| How it works | A cancer drug that hits three targets | ||||
| Next date | Dec 2026 · First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) · press release | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Merck & Co. +1 · Public MRK |
Phase 2 | Dec 2026Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Malignant Tumors and 3 more | ||||
| Open drug page | |||||
PD-L1/VEGF bispecific fusion protein |
Tasly · Public 600535.SS |
Phase 2 | 1 Jan 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC) and 6 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Crescent Biopharma +1 · Public CBIO · 6990.HK |
Phase 1/2 | Mar 2027Proof-of-concept data from the ASCEND Phase 1/2 trial expected in Q1 2027 (company guidance) | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Mar 2027 · Proof-of-concept data from the ASCEND Phase 1/2 trial expected in Q1 2027 (company guidance) · press release | ||||
| Also tested for | Locally Advanced / Metastatic Solid Tumors | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
OncoC4 · Private |
Phase 1/2 | 30 Jun 2027Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
PD-L1/VEGF bispecific antibody |
Instil Bio +1 · Public TIL · 1541.HK |
Phase 2 | 23 Jul 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 23 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, NSCLC and 3 more | ||||
| Open drug page | |||||
— |
Phase 2 | 1 Apr 2028Phase 1/2 trial completes | |||
| Next date | 1 Apr 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Malignant Solid Tumor, Advanced Solid Tumor and 2 more | ||||
| Open drug page | |||||
PD-1/VEGFR2 bifunctional antibody |
Ottimo Pharma · Private |
Phase 1/2 | Dec 2028Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Dec 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Matches
- Conditions, trial titles, drug names and codes, other names, how it works and company.
- Checked
- 17 of 17 drugs. How we check
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · openFDA updated 13 Nov 2026 · Company press releases
Ask your AI about this landscape. Connect it once, then ask in plain English.
Connect your AI
Which PD-1/VEGF bispecifics are in Phase 3, and which trial reads out first?Which should we check next?
Need a landscape built for you? Talk to us.
